Expert Panel: Optimizing Melanoma Brain Metastases Management with Modern Immunotherapy Approaches
Recent advances reshape management of melanoma brain metastases through combination immunotherapy and multidisciplinary approaches.
August 28, 2025
TAR-200 Achieves 82% Complete Response in BCG-Refractory Bladder Cancer: SunRISe-1 Results
New drug-releasing system, TAR-200, eliminated tumors in 82% of patients in phase 2 clinical trial for high-risk bladder cancer.
Pan-GI Cancer Microbiota Analysis Reveals Universal Prognostic Bacterial Signatures
Fifteen bacterial genera consistently associated with prognosis across six GI tumor types, predicting survival and metastasis risk.
Pan-GI Cancer Microbiota Analysis Reveals Universal Prognostic Bacterial Signatures Read More »
TIL Therapy Shows Promise in Heavily Pretreated Metastatic Head and Neck Cancer: Phase 2 Trial Results
TIL therapy stabilized disease in 64% of metastatic head/neck cancer patients, extending survival to 9.5 months in heavily treated cases.
Verzenio Achieves Overall Survival Milestone in Early Breast Cancer Competition”
Verzenio plus endocrine therapy offers statistically significant OS improvements over endocrine therapy alone in high-risk patients.
Verzenio Achieves Overall Survival Milestone in Early Breast Cancer Competition” Read More »
Decipher Test Identifies Prostate Cancer Patients Who Benefit Most from Chemotherapy
Molecular profiling identifies prostate cancer patients who benefit most from chemotherapy, sparing others from unnecessary side effects.
Decipher Test Identifies Prostate Cancer Patients Who Benefit Most from Chemotherapy Read More »
Age-Stratified Survival Analysis: Fertility-Preserving Hormonal Therapy vs Hysterectomy in Early-Stage Endometrial Cancer
Fertility-preserving hormonal therapy offers comparable survival to hysterectomy for women under 40 with early endometrial cancer.
FDA Issues CRL for Telix’s Breakthrough Kidney Cancer Imaging Agent TLX250-CDx Over Manufacturing Concerns
The FDA has issued a Complete Response Letter for TLX250-CDx (Zircaix), rejecting the biologics license application for this breakthrough therapy-designated PET imaging agent due to chemistry, manufacturing, and controls deficiencies rather than clinical efficacy concerns. Telix believes these manufacturing comparability issues are readily addressable, maintaining the drug’s potential as the first commercial imaging agent for
Histology Drives Lung Cancer Screening Effectiveness: Major Analysis of NELSON and NLST Trials
Screening effectiveness varies by histology, with adenocarcinoma showing 17.8-23.0% mortality reduction across trials.
Targeting ‘Undruggable’ KRAS in Pancreatic Cancer: Clinical Breakthroughs and Resistance Strategies
KRASG12C inhibitors achieve 21-33% response rates with superior safety vs standard chemo in PDAC patients.